Director at Niagen Bioscience (NAGE) receives 31,746 stock options award
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Niagen Bioscience, Inc. director Ann Cohen received a grant of stock options covering 31,746 shares of common stock. The options have an exercise price of $3.45 per share and expire on June 23, 2036. They vest 100% on June 24, 2027, and following this award she holds 31,746 options directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Cohen Ann
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 31,746 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 31,746 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 31,746 options
Exercise price: $3.45 per share
Options after grant: 31,746 options
+2 more
5 metrics
Option grant size
31,746 options
Stock Option (right to buy) covering common stock
Exercise price
$3.45 per share
Exercise price of stock options
Options after grant
31,746 options
Total derivative holdings following transaction
Vesting date
June 24, 2027
Options vest 100% on this date
Expiration date
June 23, 2036
Options expire on this date
Key Terms
Stock Option (right to buy), Grant, award, or other acquisition, Common Stock, exercise price, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
exercise price financial
"conversion_or_exercise_price: 3.4500"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-23T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
What did Ann Cohen report in the Niagen Bioscience (NAGE) Form 4 filing?
Ann Cohen reported receiving stock options for 31,746 shares of Niagen Bioscience common stock. These options were granted as a compensation award, not bought in the open market, and give her the right to purchase shares at a fixed exercise price.
What is the exercise price of the new NAGE stock options granted to Ann Cohen?
The options granted to Ann Cohen have an exercise price of $3.45 per share. This means she can later buy up to 31,746 Niagen Bioscience shares at $3.45, regardless of the market price, once the options have vested.
When do Ann Cohen’s Niagen Bioscience (NAGE) stock options vest and expire?
Ann Cohen’s stock options vest 100% on June 24, 2027. After vesting, she can exercise them any time until their expiration on June 23, 2036, subject to any applicable company or contractual restrictions on exercises.
How many Niagen Bioscience (NAGE) options does Ann Cohen hold after this Form 4 transaction?
After this grant, Ann Cohen holds 31,746 stock options directly. All of these options relate to Niagen Bioscience common stock and were acquired through this single award, rather than through market purchases or option exercises.